Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Burger PM, Dorresteijn JAN, Fiolet ATL, Koudstaal S, Eikelboom JW, Nidorf SM, Thompson PL, Cornel JH, Budgeon CA, Westendorp ICD, Beelen DPW, Martens FMAC, Steg PG, Asselbergs FW, Cramer MJ, Teraa M, Bhatt DL, Visseren FLJ, Mosterd A; LoDoCo2 Trial Investigators; UCC-SMART Study Group; REACH Registry Investigators.
Burger PM, et al.
Eur J Prev Cardiol. 2023 Dec 21;30(18):1950-1962. doi: 10.1093/eurjpc/zwad221.
Eur J Prev Cardiol. 2023.
PMID: 37409348
They may be expected to be of at least similar magnitude to those of intensified LDL-c and SBP reduction in a majority of patients already on conventional lipid-lowering and blood pressure-lowering therapy. The long-term benefits of treatment with low-dose colchicine were …
They may be expected to be of at least similar magnitude to those of intensified LDL-c and SBP reduction in a majority of patients already o …